Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
about
Chemoresistance and targeted therapies in ovarian and endometrial cancersComputational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.Fenretinide: a novel treatment for endometrial cancer.Signalling pathways in endometrial cancerEstablishment of human patient-derived endometrial cancer xenografts in NOD scid gamma mice for the study of invasion and metastasisInfluence of AKT on progesterone action in endometrial diseases.Exogenous ubiquitin modulates chronic β-adrenergic receptor-stimulated myocardial remodeling: role in Akt activity and matrix metalloproteinase expression.MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth.Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximabAkt regulates progesterone receptor B-dependent transcription and angiogenesis in endometrial cancer cellsIncreased AKT or MEK1/2 activity influences progesterone receptor levels and localization in endometriosis.Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.Activated AKT pathway promotes establishment of endometriosis.Therapeutic potential of serum and glucocorticoid inducible kinase inhibition.Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease SettingsEndometrial Carcinoma: Specific Targeted Pathways.Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why.Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.FKBP51 decreases cell proliferation and increases progestin sensitivity of human endometrial adenocarcinomas by inhibiting Akt.Concurrent interactome and metabolome analysis reveals role of AKT1 in central carbon metabolism.The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer.MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT.
P2860
Q28073246-59B353C5-D02A-4027-9658-7590B6518D43Q28543899-0AB2B182-6076-4B78-A2A8-6C4D23DD6199Q30407709-EB1AEB9A-F7FB-4A25-A109-5974E8519CDAQ34395170-B53D5526-8C7B-41E0-A125-B7672A5C09F2Q34721660-E17E858D-14AC-4663-A232-43127E3A04A0Q34776859-45273BDE-DE23-4728-A4D4-9230E516E8F3Q35617565-98FB93ED-D13E-4C9F-A888-2FF28271A2C7Q36494639-8D669E7B-AFD6-46DE-B835-5B27CA1DF392Q37240206-A83DEBA4-2EF9-4B83-A6E1-3264395AB565Q37269197-B7F187B0-3CB6-4A73-8AB5-ABC127D87D64Q37273132-86D04C3B-1E5B-4874-8361-ABDD2B52D0E7Q37361813-AFDF1BD3-CC29-4D10-81A5-B1C7A68EEF19Q37636632-600B05BF-A553-44C2-A0F7-22A3532295CBQ37707078-56905DCB-81E5-4F9F-9CBE-F700F24DF1E9Q37709202-83B33DB3-4243-473A-B529-875414821BF7Q38090700-B884FC45-165E-444A-BEDC-97559089330FQ38895754-C53E8613-084B-47FF-A6DF-696C8088793AQ39026766-99A33361-066A-4D86-B757-6577C517DB64Q39365130-870C0FAE-441F-4139-AF29-4539AA161462Q42381878-BF5901E2-5EEF-4B55-B340-5E888ECE3A4BQ47112399-2852AF08-A89A-4B41-A05B-25F659E82EC2Q52714549-103669D5-2F44-44DE-B940-AD006CC85ACBQ52799875-49D653E6-F6C7-49BB-8101-12BE0C8B9299Q54968730-9CBC4D46-6E83-4816-A158-74DCF311EE97
P2860
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@ast
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@en
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@nl
type
label
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@ast
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@en
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@nl
prefLabel
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@ast
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@en
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@nl
P2093
P2860
P1433
P1476
Inhibition of AKT with the ora ...... ial cancer cells to progestin.
@en
P2093
Bo R Rueda
Irene I Lee
J Julie Kim
Julian Schink
Zhenxiao Lu
P2860
P304
P356
10.1371/JOURNAL.PONE.0041593
P407
P577
2012-07-24T00:00:00Z